Abstract
Two green-sensitive spectrofluorometric methods were investigated for assay of rupatadine (RUP) [method I] and its binary mixture with montelukast (MKT) [method II]. Method I depends on measuring native fluorescence of RUP in the presence of 0.10 M H2SO4 and 0.10%w/v sodium dodecyl sulfate at 455 nm after excitation at 277 nm. The range of the first method was 0.20–2.00 µg ml−1 with detection and quantitation limits of 59.00 and 179.00 ng ml−1, respectively. Method II depends on the first derivative synchronous spectrofluorometry. The derivative intensities were measured for the two drugs in an aqueous solution containing Mcllvaine's buffer pH 2.60 at fixed Δλ of 140 nm. Each drug was estimated at zero-contribution of the other. The intensity was measured at 261 and 371 nm for RUP and MKT, respectively. The method was linear over 0.10–4.00 and 0.20–1.60 µg ml−1 with limits of detection 31.00 and 66.00 ng ml−1 and limits of quantitation 94.00 and 200.00 ng ml−1 for RUP and MKT, respectively. The method was extended to determine this mixture in laboratory-prepared mixtures and combined tablets. Method validation was performed according to ICH guidelines. Statistical interpretation of data revealed good agreement with the comparison method. Method greenness was confirmed by applying three different assessment tools.
Highlights
Rupatadine (RUP) fumarate is 8-Chloro-11-[1-[(5-methylpyridin-3-yl)methyl]piperidin-4ylidine]-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine(2E)-but-2-enedioate
RUP and MKT are co-formulated in tablet dosage forms like (Rupanex M®, Montyrup®) by pharmaceutical ratio 1 : 1. It has been found that this combination is more effective than a single one in control of allergic rhinitis symptoms
Different values of Δλ were examined to improve the resolution of this mixture. electronic supplementary material, figure S1 shows that RUP and MKT synchronous fluorescence spectra were overlapped
Summary
Rupatadine (RUP) fumarate (figure 1a) is 8-Chloro-11-[1-[(5-methylpyridin-3-yl)methyl]piperidin-4ylidine]-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine(2E)-but-2-enedioate. RUP is a secondgeneration non-sedating antihistamine with platelet-activating factor antagonist activity that is prescribed for the treatment of allergic rhinitis, conjunctivitis and chronic idiopathic urticaria. It is given as the fumarate doses are expressed in terms of the base; RUP fumarate 12.80 mg is equivalent to about 10.00 mg of RUP. MKT is a selective leukotriene receptor antagonist that is approved in cases of allergic rhinitis and chronic asthma. It is used as a prophylactic agent for exercise-induced asthma [3]. RUP and MKT are co-formulated in tablet dosage forms like (Rupanex M®, Montyrup®) by pharmaceutical ratio 1 : 1. It has been found that this combination is more effective than a single one in control of allergic rhinitis symptoms
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.